TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06576271: A Phase 1, First-time-in-human, Four-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active System

Sponsor: GlaxoSmithKline · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 142 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$3,988,200

Rescue Site Savings

+$2,627,520

Unlock Full NCT06576271 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06576271 Rescue Dossier →